~~<i id='5A14C14969'><strike id='5A14C14969'><tt id='5A14C14969'><pre id='5A14C14969'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：leisure time 2025-09-30 02:51:15 Page View：56643

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： CDC recommends rationing of RSV shot due to shortages
Next article： Medicare details structure of new drug price negotiation program

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Telehealth options flood the market as retailers push virtual care

AdobeWhenpatientsgoshoppingtoday,theymightfindthemselvescheckingoutwithmorethanthevitaminsorbulktoil

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

The Bio Revolution is changing business and society

Culturedmeatismadeusingtissue-culturetechnology,alabprocessbywhichanimalcellsaregrowninvitro.Zhdanov